Pros | ![]() Beats FD returns for both 3Y & 5Y. | ![]() Lower probablity of downside risk. ![]() Recovers losses quickly. ![]() Larger AUM within category. | ||
Cons | ![]() Has not generated consistent returns. ![]() Does not beat the benchmark consistently. ![]() Higher probablity of downside risk. | - |
INDMoney rank | 18/19 | 2/19 | ||
Category,Subcateogry | Equity,Mid-Cap | Equity,Mid-Cap | ||
Fund Age | 12 Years | 12 Years | ||
Fund Size | 10649 Cr | 72610 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹100 | ||
Expense Ratio | 0.89% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | Nifty Midcap 150 TR INR | Nifty Midcap 150 TR INR |
No of Holdings | 90 | 81 | ||
Top 5 Holdings | Phoenix Mills Ltd (2.43%) Solar Industries India Ltd (2.36%) Coforge Ltd (2.29%) Persistent Systems Ltd (2.13%) Ajanta Pharma Ltd (2%) | Max Financial Services Ltd (4.04%) Indian Hotels Co Ltd (3.69%) The Federal Bank Ltd (3.39%) Coforge Ltd (3.36%) Ipca Laboratories Ltd (3.27%) | ||
No of Sectors | 12 | 10 | ||
Top 3 Sectors | Consumer Cyclical (19.93%) Financial Services (19.03%) Industrial (14.38%) | Financial Services (25.64%) Consumer Cyclical (19.54%) Health (13.56%) | ||
Equity % | 97.35% | 93% | ||
Debt % | - | - | ||
P/E | 27.09 | 21.13 | ||
P/B | 4.19 | 3.1 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 1.43% | 2.76% | ||
3-Month Return | -2.78% | 3.51% | ||
6-Month Return | -8.88% | -3.2% | ||
1-Year Return | 5.51% | 11.2% | ||
3-Year Return | 16.05% | 25.37% | ||
5-Year Return | 28.65% | 33.9% |
Sharpe | 0.55 | 1.11 | ||
Alpha | -3.9 | 5.02 | ||
Beta | 0.94 | 0.88 | ||
Standard Deviation | 16.66 | 15.54 | ||
Information Ratio | -1.32 | 1.19 |
Description | UTI Mid Cap Fund-Growth Option- Direct is an equity fund.The fund could potentially beat inflation in the long-run. | HDFC Mid-Cap Opportunities Fund -Direct Plan - Growth Option is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Ankit Agarwal | Chirag Setalvad |